Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 75%High 1 · 25%

Serious adverse events · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.98 [0.81, 1.17]
2 studies · 2235 participants
Moderate

Serious adverse events · patients with chronic obstructive pulmonary disease

Benralizumab 10 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.9 [0.69, 1.17]
1 study · 1129 participants
Moderate

Serious adverse events · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.9 [0.75, 1.08]
3 studies · 2333 participants
Moderate

Serious adverse events · people with asthma

Benralizumab subcutaneous (SC) leads to lower serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Risk ratio 0.76 [0.62, 0.93]
5 studies · 3304 participants
High